The concomitant use of tyrosine kinase inhibitors and proton pump inhibitors: Prevalence, predictors, and impact on survival and discontinuation of therapy in older adults with cancer - Sharma, Manvi; Holmes, Holly M.; Mehta, Hemalkumar B.; Chen, Hua; Aparasu, Rajender R.; Shih, Ya‐Chen T.; Giordano, Sharon H.; Johnson, Michael L. (Cancer, 2019)
Keywords: Adults; Aged; Aged, 80 and over; and End Results (SEER)‐Medicare; Cancer; Chronic myeloid leukemia; Confidence intervals; Deprescriptions; Drug interaction; Drug Interactions; drug‐drug interaction; elderly; Epidemiology; Exposure; Female; Gastroesophageal Reflux - complications; Gastroesophageal Reflux - drug therapy; Government programs; Hazards; Health care; Health hazards; Humans; Information Storage and Retrieval; Inhibitors; Kidney cancer; Leukemia; Liver; Liver cancer; Lung cancer; Male; Medicare; Medicare Part D; Myeloid leukemia; Neoplasms - complications; Neoplasms - drug therapy; Older people; Oncology; Pancreatic cancer; Peptic Ulcer - drug therapy; Polypharmacy; predictors; prevalence; Proportional Hazards Models; Protein Kinase Inhibitors - therapeutic use; Protein-Tyrosine Kinases - antagonists & inhibitors; Proton pump inhibitors; Proton Pump Inhibitors - therapeutic use; Renal cell carcinoma; Retrospective Studies; SEER Program; Statistical analysis; Surveillance; Survival; Survival Rate; Therapy; Tyrosine; Tyrosine kinase inhibitors; United States; United States; predictors; tyrosine kinase inhibitors; prevalence; proton pump inhibitors; Surveillance; elderly; survival; and End Results (SEER)-Medicare; Epidemiology; drug-drug interaction; Medicare Part D; polypharmacy